【转|太平洋医药-先声药业深度】创新药密集兑现,未来持续增长可期

远峰电子
27 May

文章转自2025年2月13日太平洋医药团队报告,分析师:谭紫媚/张懿投资要点神经专科制药龙头地位稳固(1)先必新舌下片获批,成为又一款能够改善卒中预后的重磅药物先必新注射液于2020年获批上市后销售额快速增长,2020-2023年CAGR达749.9%。2024年12月,先必新舌下片获批上市,有望与先必新注射液构成涵盖卒中全病程的序贯疗法。结合舌下给药的便捷性,急性脑卒中患者的依从性将有所提高。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10